Government hostility to biopharmaceutical industry reduces access to innovative drugs
Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need new drugs either have their access long delayed, or denied.
Multi-payer pharmacare will fail Canadians
Private insurers want Canada to embrace a multi-payer pharmacare system without the tools necessary to protect public interests, promote equity, and ensure value.
